Eli Lilly on Friday crossed the $1 trillion market-cap threshold, becoming the first drugmaker to ever reach that milestone.

New GLP-1 weight-loss drugs may preserve muscle, protect skin, and reduce the risk of "Ozempic face." Experts explain what ...

NBC News' Anne Thompson joins "Here's the Scoop" co-host Yasmin Vossoughian to talk about why some people are microdosing GLP ...

Nausea, a major hurdle for millions using weight-loss drugs like Ozempic, may soon be a thing of the past. Researchers are ...

Bravo TV host Andy Cohen told the TODAY show that microdosing a GLP-1 drug helped him lose “a good chunk of weight.” The ...

GLP-1 RAs are associated with a 62% reduction in 5-year mortality in colon cancer patients, especially those with high obesity. The study's findings remained significant after adjusting for ...

Millions of Americans have successfully lost weight using drugs like Wegovy and Zepbound, but unpleasant side ...

A growing number of people are searching for weight loss options that feel manageable in daily life. Many of the current ...

By 2030, households with GLP-1 users are projected to represent 35% of all food and beverage units sold, the consumer ...

Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) use was significantly associated with a reduced odds of five-year mortality, but this protective effect was found to be statistically significant ...

Orforglipron is Lilly’s oral GLP-1 in phase 3 development as a treatment for diabetes and obesity. The FDA is expected to approve the drug in March 2026. Lilly’s November news release states that the ...

Eli Lilly stock inches higher as the company joins the coveted trillion-dollar club. Citi analysts believe LLY shares will ...